Search

Your search keyword '"Domont J"' showing total 181 results

Search Constraints

Start Over You searched for: Author "Domont J" Remove constraint Author: "Domont J"
181 results on '"Domont J"'

Search Results

1. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

23. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

24. Série de radiothérapie en conditions stéréotaxiques de métastases cérébrales précédée ou non d’une irradiation panencéphalique dite prophylactique

26. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

27. LB-05PHASE III TRIAL EXPLORING THE COMBINATION OF BEVACIZUMAB AND LOMUSTINE IN PATIENTS WITH FIRST RECURRENCE OF A GLIOBLASTOMA: THE EORTC 26101 TRIAL

28. OS5.2 Health-Related Quality of Life (HRQoL) in patients with progressive glioblastoma treated with combined bevacizumab and lomustine versus lomustine only (randomized phase III EORTC study 26101)

30. LB-05PHASE III TRIAL EXPLORING THE COMBINATION OF BEVACIZUMAB AND LOMUSTINE IN PATIENTS WITH FIRST RECURRENCE OF A GLIOBLASTOMA: THE EORTC 26101 TRIAL

31. Imaging of gliomas at 1.5 and 3 Tesla - A comparative study

33. A Randomized Multicentre Phase Ii Study of Pazopanib Plus Best Supportive Care (Bsc) Vs Bsc Alone in Metastatic Gastrointestinal Stromal Tumors (Gist) Resistant to Imatinib and Sunitinib

35. Long-Term Outcome of Dasatinib First-Line Treatment in Gastrointestinal Stromal Tumors: a Multicenter Two Stage Phase Ii Trial Sakk 56/07

36. Benefit of Maintenance Therapy with Trabectedin (T) Beyond the 6 First Cycles: Results of a Prospective Randomized Phase Ii Trial Comparing Interruption Vs. Continuation of T in Patients (Pts) with Advanced Soft Tissue Sarcoma (Asts): an Update

37. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis.

42. P1-06-12: Circulating Tumor Cells (CTC) Monitoring during Phase II Study with Lapatinib (L) and Capecitabine (C) in Patients with Brain Metastases from HER2−Positive (+) Metastatic Breast Cancer (MBC) before Whole Brain Radiotherapy (WBR): LANDSCAPE Study.

44. Influence of imatinib interruption and imatinib rechallenge on the residual tumor volume in patients with advanced GIST: Results of the BFR14 prospective French Sarcoma Group randomized phase III trial.

45. LANDSCAPE: An FNCLCC phase II study with lapatinib (L) and capecitabine (C) in patients with brain metastases (BM) from HER2-positive (+) metastatic breast cancer (MBC) before whole-brain radiotherapy (WBR).

47. High-grade gliomas treated with bevacizumab: Assessment of tumor response with functional MR.

50. Abstract P4-10-13: Therapeutic Delays, Mode of Diagnosis and Surgical Treatment of Operable Invasive Breast Cancer (BC) in Elderly Versus Non Elderly Patients in the Community

Catalog

Books, media, physical & digital resources